Is Ruibai administered via subcutaneous or intramuscular injection?

Neulasta, also known as recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection, is generally administered via subcutaneous injection. The specific details are as follows:

Recombinant human granulocyte colony-stimulating factor injection is typically prepared by opening the vial and drawing the appropriate amount of medication into a syringe, followed by intravenous or subcutaneous administration under sterile conditions. Its primary function is to stimulate granulopoiesis and increase neutrophil counts. After subcutaneous injection, it regulates granulocyte production in the bone marrow, promoting proliferation and differentiation, while also enhancing the functional activity of terminally differentiated granulocytic cells. It is indicated for treating neutropenia caused by various conditions and for accelerating neutrophil recovery following bone marrow transplantation. However, it should be strictly avoided in patients with severe hepatic, renal, cardiac, or pulmonary dysfunction, as well as in those with myeloid leukemia who have not shown significant reduction in immature granulocytes in the bone marrow.

In summary, recombinant human granulocyte colony-stimulating factor injection is usually given subcutaneously. Patients requiring this medication must first undergo evaluation at a正规 medical institution and use the drug only under the guidance of a qualified physician to prevent potential harm to the body.